The conduct of clinical trials has become increasingly a global enterprise. However, regulation of trials is still largely organized on a regional basis. Thus it matters, from the perspective of the credibility of the results, where a specific trial of interest was conducted. So it was of great interest and the cause of perhaps some apprehension when the first vaccine to be approved for COVID-19 came from Russia, based on clinical trials conducted in Russia, a country without a strong tradition of clinical trials and especially randomized clinical trials.¹ In this issue of Clinical Trials, we present three contributions focused on the topic of clinical trials in Russia.

中文翻译：

---

俄罗斯临床试验

临床试验的进行已日益成为一个全球性的企业。然而，审判的监管仍然主要是按区域组织的。因此，从结果可信度的角度来看，在何处进行感兴趣的特定试验很重要。因此，当第一个被批准用于 COVID-19 的疫苗来自俄罗斯时，基于在俄罗斯进行的临床试验引起了极大的兴趣，并且可能引起了一些担忧，俄罗斯没有强大的临床试验传统，尤其是随机临床试验。 . ¹在本期《临床试验》中，我们介绍了三篇关于俄罗斯临床试验主题的文章。